The role of chest X-ray in the diagnosis of bacteriologically confirmed pulmonary tuberculosis in hospitalised Xpert MTB/RIF-negative patients
- Wakjira Kebede1,2,3,
- Gemeda Abebe1,2,
- Esayas Kebede Gudina4⇑,
- Elias Kedir5,
- Thuy Ngan Tran3 and
- Annelies Van Rie3
- 1Mycobacteriology Research Center, Jimma University, Jimma, Ethiopia
- 2School of Medical Laboratory Science, Institute of Health, Jimma University, Jimma, Ethiopia
- 3Department of Family Medicine and Population Health (FAMPOP), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- 4Department of Internal Medicine, Jimma University Medical Center, Jimma University, Jimma, Ethiopia
- 5Department of Radiology, Jimma University Medical Center, Jimma University, Jimma, Ethiopia
- Wakjira Kebede. E-mail: wakjirakebede{at}yahoo.com
Abstract
Introduction The role of a chest X-ray (CXR) to diagnose active tuberculosis (TB) in symptomatic patients who have a negative Xpert MTB/RIF (Xpert) test result is unclear. This study aimed to assess the performance of CXR and the value of CXR findings for a prediction tool to identify cases of active pulmonary TB among symptomatic, Xpert-negative hospitalised patients.
Methods Xpert-negative patients hospitalised between January and July 2019 at Jimma University Medical Center in Ethiopia were assessed by mycobacterial culture and CXR. CXR was interpreted by a clinician for clinical decision making and by a radiologist for research purposes. Using bacteriological confirmation as the reference standard, the performance of CXR to diagnose active TB was assessed by the area under the receiver operating characteristic (AUC) curve, predictors of active TB were identified using bivariate and multivariate logistic regression analyses.
Results Of 247 Xpert-negative patients, 38% and 40% were classified as suggestive of TB by clinician and radiologist, respectively. Of the 39 (15.8%) bacteriologically confirmed cases, 69% and 79% were classified as having CXR findings suggestive of TB by clinician or radiologist, respectively. While there was a strong association between bacteriologically confirmed TB and CXR classified by clinician as suggestive of TB (aOR 2.7, 95% CI: 1.2–6.6), CXR with signs typical of TB (aOR 5.3, 95% CI: 2.1–14.4) or compatible with TB (aOR 5.1, 95% CI: 1.3–20.0), the positive predictive value of the CXR was low (27% and 34% for classification by clinician and radiologist, respectively). The addition of CXR findings by clinician or radiologist to clinical characteristics did not improve the performance of the prediction tool, with similar risk classification distribution, AUCs and negative and positive prediction values.
Conclusion Despite the strong association between CXR findings and active TB among hospitalised Xpert negative individuals, CXR findings did not improve the performance of a risk prediction tool based solely on clinical symptoms. Countries with a high TB/HIV burden should urgently replace Xpert by the more sensitive Xpert ultra assay to improve the diagnosis of active TB.
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Kebede has nothing to disclose.
Conflict of interest: Dr. Abebe has nothing to disclose.
Conflict of interest: Dr. Gudina has nothing to disclose.
Conflict of interest: Dr. Kedir has nothing to disclose.
Conflict of interest: Dr. Tran has nothing to disclose.
Conflict of interest: Dr. Van Rie has nothing to disclose.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received September 29, 2020.
- Accepted November 13, 2020.
- Copyright ©ERS 2020
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.